These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27456908)

  • 21. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3].
    Kotov SV; Kudlay DA; Lizhdvoy VY; Stashuk GA; Magomedova SB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):107-115. PubMed ID: 31156249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
    Kim YJ; Lee HY; Lee JY; Yoon TY
    Int J Dermatol; 2015 Apr; 54(4):456-8. PubMed ID: 23786157
    [No Abstract]   [Full Text] [Related]  

  • 24. [Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].
    Bykova OV; Maslova OI; Guseva MR; Boĭko SIu; Totolian NA; Matveeva TA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):4-10. PubMed ID: 15270293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphea secondary to interferon beta1b injection: a case and review of the literature.
    Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis.
    Wroe SJ
    J Int Med Res; 2005; 33(3):309-18. PubMed ID: 15938592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of rituximab originator (MabThera
    Perez T; Rico A; Boutière C; Maarouf A; Roudot M; Honoré S; Pelletier J; Bertault-Peres P; Audoin B
    Mult Scler; 2021 Apr; 27(4):585-592. PubMed ID: 32180508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
    Higurashi N; Hamano S; Eto Y
    No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphocytes in the treatment with interferon beta-1 b.
    Pavelek Z; Vyšata O; Klímová B; Andrýs C; Vokurková D; Vališ M
    Mult Scler Relat Disord; 2017 Nov; 18():29-32. PubMed ID: 29141817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosis.
    Castillo-Álvarez F; Pérez-Matute P; Oteo JA; Marzo-Sola ME
    Neurologia (Engl Ed); 2021 Sep; 36(7):495-503. PubMed ID: 34537163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.
    Schultheiss HP; Piper C; Sowade O; Waagstein F; Kapp JF; Wegscheider K; Groetzbach G; Pauschinger M; Escher F; Arbustini E; Siedentop H; Kuehl U
    Clin Res Cardiol; 2016 Sep; 105(9):763-73. PubMed ID: 27112783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon beta-1b: a 1-year follow-up.
    Gerschlager W; Beisteiner R; Deecke L; Dirnberger G; Endl W; Kollegger H; Lindinger G; Vass K; Lang W
    Eur Neurol; 2000; 44(4):205-9. PubMed ID: 11096218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
    Sabanov AV; Luneva AV; Matveev NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.